Philogen Provides Corporate Update
Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft–tissue sarcoma and glioblastoma are on track. OncoFAP shows potent activity […]
Continue Reading